Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Irisin as a muscle-derived hormone stimulating thermogenesis--a critical update.

Hofmann T, Elbelt U, Stengel A.

Peptides. 2014 Apr;54:89-100. doi: 10.1016/j.peptides.2014.01.016. Epub 2014 Jan 26. Review.

PMID:
24472856
2.

Irisin: what promise does it hold?

Elbelt U, Hofmann T, Stengel A.

Curr Opin Clin Nutr Metab Care. 2013 Sep;16(5):541-7. doi: 10.1097/MCO.0b013e328363bc65. Review.

PMID:
23799326
3.

Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies.

Kurdiova T, Balaz M, Vician M, Maderova D, Vlcek M, Valkovic L, Srbecky M, Imrich R, Kyselovicova O, Belan V, Jelok I, Wolfrum C, Klimes I, Krssak M, Zemkova E, Gasperikova D, Ukropec J, Ukropcova B.

J Physiol. 2014 Mar 1;592(5):1091-107. doi: 10.1113/jphysiol.2013.264655. Epub 2013 Dec 2.

4.

Browning of white fat: does irisin play a role in humans?

Elsen M, Raschke S, Eckel J.

J Endocrinol. 2014 Jul;222(1):R25-38. doi: 10.1530/JOE-14-0189. Epub 2014 Apr 29. Review.

5.

Physiology and role of irisin in glucose homeostasis.

Perakakis N, Triantafyllou GA, Fernández-Real JM, Huh JY, Park KH, Seufert J, Mantzoros CS.

Nat Rev Endocrinol. 2017 Jun;13(6):324-337. doi: 10.1038/nrendo.2016.221. Epub 2017 Feb 17. Review.

PMID:
28211512
6.

Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance.

Moreno-Navarrete JM, Ortega F, Serrano M, Guerra E, Pardo G, Tinahones F, Ricart W, Fernández-Real JM.

J Clin Endocrinol Metab. 2013 Apr;98(4):E769-78. doi: 10.1210/jc.2012-2749. Epub 2013 Feb 22.

7.

Irisin exerts dual effects on browning and adipogenesis of human white adipocytes.

Zhang Y, Xie C, Wang H, Foss RM, Clare M, George EV, Li S, Katz A, Cheng H, Ding Y, Tang D, Reeves WH, Yang LJ.

Am J Physiol Endocrinol Metab. 2016 Aug 1;311(2):E530-41. doi: 10.1152/ajpendo.00094.2016. Epub 2016 Jul 19.

8.

Irisin: 'fat' or artefact.

Crujeiras AB, Pardo M, Casanueva FF.

Clin Endocrinol (Oxf). 2015 Apr;82(4):467-74. doi: 10.1111/cen.12627. Epub 2014 Nov 7. Review.

PMID:
25287317
9.

FNDC5/irisin is not only a myokine but also an adipokine.

Roca-Rivada A, Castelao C, Senin LL, Landrove MO, Baltar J, Belén Crujeiras A, Seoane LM, Casanueva FF, Pardo M.

PLoS One. 2013 Apr 11;8(4):e60563. doi: 10.1371/journal.pone.0060563. Print 2013.

10.

Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans.

Lee P, Linderman JD, Smith S, Brychta RJ, Wang J, Idelson C, Perron RM, Werner CD, Phan GQ, Kammula US, Kebebew E, Pacak K, Chen KY, Celi FS.

Cell Metab. 2014 Feb 4;19(2):302-9. doi: 10.1016/j.cmet.2013.12.017.

11.

Exercise-mimicking treatment fails to increase Fndc5 mRNA & irisin secretion in primary human myotubes.

Kurdiova T, Balaz M, Mayer A, Maderova D, Belan V, Wolfrum C, Ukropec J, Ukropcova B.

Peptides. 2014 Jun;56:1-7. doi: 10.1016/j.peptides.2014.03.003. Epub 2014 Mar 16.

PMID:
24642356
12.

[The secretory function of skeletal muscles and its role in energy metabolism and utilization].

Halmos T, Suba I.

Orv Hetil. 2014 Sep 14;155(37):1469-77. doi: 10.1556/OH.2014.29959. Review. Hungarian.

PMID:
25194869
13.

[Irisin: a messenger from the gods?].

Moreno M, Moreno-Navarrete JM, Fernández-Real JM.

Clin Investig Arterioscler. 2014 May-Jun;26(3):140-6. doi: 10.1016/j.arteri.2013.11.002. Epub 2013 Dec 13. Review. Spanish.

PMID:
24332558
14.

[Irisin--a new mediator of energy homeostasis].

Pukajło K, Kolackov K, Łaczmański Ł, Daroszewski J.

Postepy Hig Med Dosw (Online). 2015 Feb 21;69:233-42. doi: 10.5604/17322693.1141097. Review. Polish.

15.

FNDC5/irisin, a molecular target for boosting reward-related learning and motivation.

Zsuga J, Tajti G, Papp C, Juhasz B, Gesztelyi R.

Med Hypotheses. 2016 May;90:23-8. doi: 10.1016/j.mehy.2016.02.020. Epub 2016 Mar 2.

PMID:
27063080
16.

The effects of acute and chronic exercise on PGC-1α, irisin and browning of subcutaneous adipose tissue in humans.

Norheim F, Langleite TM, Hjorth M, Holen T, Kielland A, Stadheim HK, Gulseth HL, Birkeland KI, Jensen J, Drevon CA.

FEBS J. 2014 Feb;281(3):739-49. doi: 10.1111/febs.12619. Epub 2013 Dec 10.

17.

Irisin and Myonectin Regulation in the Insulin Resistant Muscle: Implications to Adipose Tissue: Muscle Crosstalk.

Gamas L, Matafome P, Seiça R.

J Diabetes Res. 2015;2015:359159. doi: 10.1155/2015/359159. Epub 2015 May 5. Review.

18.

Irisin/FNDC5--An updated review.

Panati K, Suneetha Y, Narala VR.

Eur Rev Med Pharmacol Sci. 2016;20(4):689-97. Review.

19.

Does IRISIN Have a BRITE Future as a Therapeutic Agent in Humans?

Irving BA, Still CD, Argyropoulos G.

Curr Obes Rep. 2014 Feb 2;3:235-41. doi: 10.1007/s13679-014-0091-1. eCollection 2014. Review.

20.

Leptin administration activates irisin-induced myogenesis via nitric oxide-dependent mechanisms, but reduces its effect on subcutaneous fat browning in mice.

Rodríguez A, Becerril S, Méndez-Giménez L, Ramírez B, Sáinz N, Catalán V, Gómez-Ambrosi J, Frühbeck G.

Int J Obes (Lond). 2015 Mar;39(3):397-407. doi: 10.1038/ijo.2014.166. Epub 2014 Sep 9.

PMID:
25199621

Supplemental Content

Support Center